Intuity Medical’s POGO Automatic ®, the First and Only FDA-Cleared Automatic Blood Glucose Monitor, Now Covered by Medicare Part B

CMS establishes new Medicare coverage codes for the one-step automatic blood glucose monitor, expanding access to millions of seniors living with diabetes

Intuity Medical, Inc., a medical technology company committed to making it easier to live with diabetes, announced today that its POGO Automatic® Blood Glucose Monitoring (ABGM) system, featuring one-step testing, is now covered by Medicare Part B. This decision expands access to the innovative monitor for the 16.5 million seniors age 65 and up living with diabetes.

The Centers for Medicare and Medicaid Services (CMS) created two new coverage codes specifically for POGO Automatic, recognizing this new and significantly different technology compared to traditional blood glucose meters (BGMs). POGO Automatic features an all-in-one design that integrates testing supplies into a 10-test cartridge.

As the first and only FDA-cleared automatic blood glucose monitoring (ABGM) system on the market, POGO Automatic revolutionizes diabetes management by allowing people with diabetes (PWD) to easily test their glucose levels without disrupting their daily activities. Its one-step process automates the multiple-step glucose monitoring process associated with traditional BGMs, making it easier for many seniors to check their blood glucose.

Recognized by healthcare professionals for its user-friendly design which can improve testing compliance, POGO Automatic is endorsed as the ideal solution for many diabetes patients by Rosemarie Lajara, MD, an endocrinologist with Southern Endocrinology & Diabetes Associates, P.A. in Plano, Texas:

“Many people with diabetes continue to rely on glucose monitors for tracking their blood sugar levels, particularly within the Medicare population, which often includes patients with dexterity, visual, or physical challenges that make traditional self-monitoring blood glucose (SMBG) meters cumbersome and challenging. Patients desire options, and currently, there is no meter like this one. POGO Automatic is an all-in-one automated product that streamlines the process. The extension of POGO Automatic’s use to our Medicare patients is a positive development, as it eliminates numerous manual steps, simplifying glucose monitoring throughout the day, which can lead to increased testing compliance and metabolic control.”

Automating blood glucose testing steps address an unmet need for many patients who find traditional blood glucose meters, test strips, lancets, and lancing devices challenging to handle. The new coverage codes – Healthcare Common Procedure Coding System (HCPCS) codes E2104 for the monitor for use with integrated lancing/blood sample testing cartridge and A4271 for the integrated lancing and blood sample testing cartridges– allow Medicare beneficiaries, who previously could not access this new technology, to obtain POGO Automatic using their Medicare Part B coverage.

“POGO Automatic bridges the gap between cumbersome traditional BGMs that the vast majority of seniors with diabetes rely on today and CGMs, which, despite their clinical benefits, can be burdensome to wear and may cause skin irritation issues,” said George Zamanakos, CEO and President of Intuity Medical. “With Medicare now covering POGO Automatic, millions of seniors finally have access to a needed alternative that simplifies blood glucose monitoring to one step. This empowers them to manage their diabetes and lets them live life on their own terms.”

Intuity Medical is actively working with a network of large retail pharmacies so patients can fulfill their Medicare prescriptions as soon as possible. For more information on POGO Automatic, visit GoodtoPogo.com.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”